|
Comment |
Serum vascular endothelial growth factor-B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. Cheng F et al. (2015) To determine serum vascular endothelial growth factor B levels in polycystic ovary syndrome, their association with insulin resistance and β-cell dysfunction, and the effect of metformin on serum vascular endothelial growth factor B levels. A cross-sectional, interventional study. We recruited 103 women with polycystic ovary syndrome and 96 age-matched healthy controls. Serum vascular endothelial growth factor B levels were determined in all participants, and 44 polycystic ovary syndrome patients randomly received metformin. We measured vascular endothelial growth factor B levels in healthy controls and women with polycystic ovary syndrome before and after metformin treatment. Women with polycystic ovary syndrome had higher serum vascular endothelial growth factor B levels, which decreased with metformin treatment. In the lean and overweight/obese groups, patients with polycystic ovary syndrome had higher plasma vascular endothelial growth factor B levels than did healthy controls (P < 0.05). Vascular endothelial growth factor B levels were correlated with body mass index, body fat percentage, M values, homeostasis model assessment of insulin resistance, and β-cell function indices. A multiple linear regression analysis showed that vascular endothelial growth factor B level was associated with M values after adjusting for age, body mass index, serum sex hormones, and serum lipids in women with polycystic ovary syndrome. Serum vascular endothelial growth factor B is significantly higher in women with polycystic ovary syndrome and is closely and positively related to insulin resistance. Metformin treatment reduces vascular endothelial growth factor B levels and ameliorates insulin resistance. This article is protected by copyright. All rights reserved.//////////////////
|